miR-3074-3p promotes myoblast differentiation by targeting Cav1

Bora Lee1,2, Yeo Jin Shin1, Seung-Min Lee1, Young Hoon Son1, Yong Ryoul Yang1,∗ & Kwang-Pyo Lee1,2,∗

1Aging Research Center, Korea Research Institute of Bioscience and Biotechnology (KIRIBB), Daejeon 34141, 2Department of Biomolecular Science, KIRIBB School of Bioscience, Korea University of Science and Technology (UST), Daejeon 34113, Korea

INTRODUCTION

Muscle fibers are generally formed as multinucleated fibers that are differentiated from myoblasts. Several reports have identified transcription factors and proteins involved in the process of muscle differentiation, but the roles of microRNAs (miRNAs) in myogenesis remain unclear. Here, comparative analysis of the miRNA expression profiles in mouse myoblasts and gastrocnemius (GA) muscle uncovered miR-3074-3p as a novel miRNA showing markedly reduced expression in fully differentiated adult skeletal muscle. Interestingly, elevating miR-3074-3p promoted myogenesis in C2C12 cells, primary myoblasts, and HSMMs, resulting in increased mRNA expression of myogenic makers such as Myog and MyHC. Using a target prediction program, we identified Caveolin-1 (Cav1) as a target mRNA of miR-3074-3p and verified that miR-3074-3p directly interacts with the 3’ untranslated region (UTR) of Cav1 mRNA. Consistent with the findings in miR-3074-3p-overexpressing myoblasts, knockdown of Cav1 promoted myogenesis in C2C12 cells and HSMMs. Taken together, our results suggest that miR-3074-3p acts as a positive regulator of myogenic differentiation by targeting Cav1. [BMB Reports 2020; 53(5): 278-283]

RESULTS

A mimic of miR-3074 promotes myogenic differentiation and fusion in myoblasts

We previously reported the expression of miRNAs in mouse...
muscle and mouse myoblasts using RNA-seq (20, 21). To identify miRNAs regulating myogenic differentiation, we compared the expression of pre-miRNAs between primary myoblasts and gastrocnemius (GA) muscle tissues isolated from 6-month-old mice. Among the 85 pre-miRNAs that showed significant changes (P < 0.001) between myoblasts and GA muscle tissues (Fig. 1A), 47 pre-miRNAs were significantly downregulated and 38 pre-miRNAs were upregulated in GA muscle tissues (Supplementary Tables 1 and 2). miR-3074 was one of the miRNAs with higher abundance in myoblasts, indicating its important role in the maintenance of homeostasis in myoblast cells. To investigate the role of miR-3074, we over-expressed a mimic (M) of miR-3074 in C2C12 cells and then induced myogenic differentiation. After 48 hr, we analyzed the expression levels of myogenic markers, such as Myog and MyHC, by qRT-PCR (Fig. 1B). miR-3074 significantly upregulated the myogenic markers. In addition, miR-3074 promoted myogenesis in primary myoblasts, resulting in increased expression of myogenic markers, such as Myog and MyHC (Fig. 1C). Consistently, the proportion of myotubes with more than two nuclei was significantly increased in primary myoblasts transfected with M-miR-3074 relative to those transfected with control mimic (M-Ctrl) (Fig. 1D). Since we found no significant change showing a similar absorbance in colorimetric assay using CCK-8 (Fig. 1E), these results suggested that miR-3074-3p promoted myogenesis in a cell cycle-independent manner.

**miR-3074-3p regulates Cav1 expression by targeting its 3’ UTR**

Since pre-miRNA is generally processed into two mature miRNAs (22, 23), we overexpressed either miR-3074-3p or miR-3074-5p in C2C12 cells and induced myogenic differentiation. Although the expression of both mature miRNA strands decreased during myogenesis, only miR-3074-3p was able to promote myogenesis in C2C12 cells (data not shown). To identify potential targets of miR-3074-3p, we used the target prediction algorithm TargetScan (www.targetscan.org). One of the identified potential targets was Cav1 (Fig. 2A), a structural protein component of caveolae, which has been shown to control satellite cell activation during muscle repair (24). To verify whether miR-3074-3p can regulate Cav1 expression, we performed a luciferase reporter assay using a construct containing the luciferase-3’ UTR of Cav1 and M-miR-3074-3p. M-miR-3074-3p reduced luciferase activity, which was effectively abolished by deletion of the miR-3074-3p site on the 3’ UTR (Fig. 2B). To further confirm that Cav1 is regulated by miR-3074-3p, we transfected M-miR-3074-3p into primary myoblasts and C2C12 cells and analyzed the expression of Cav1. As anticipated, Cav1 protein content was decreased in M-miR-3074-3p-overexpressing cells (Fig. 2C). Since Cav3 protein content was not altered by elevating miR-3074-3p, miR-3074-3p may not affect the switching or compensation between Caveolin isoforms. Consistent with our RNA-seq data, the expression of

---

**Fig. 1.** Elevating miR-3074 promoted myoblast differentiation. (A) Differentially expressed pre-miRNAs between primary myoblasts (n = 4) and gastrocnemius (GA) muscle tissues (n = 6) isolated from 6-month-old mice. The read count of pre-miR-3074 was significantly decreased in GA muscle tissues. (B) Relative mRNA expression of Myog and MyHC in C2C12 cells transfected with 100 nM miR-3074 mimic (M) or mimic control (Ctrl). (C) Relative mRNA expression of Myog and MyHC in primary myoblasts transfected with 30 nM M-miR-3074 or M-Ctrl. (D) Representative immunofluorescence images of differentiated primary myoblasts transfected with M-miR-3074 relative to those transfected with control mimic (M-Ctrl) (Fig. 1D). Since we found no significant change showing a similar absorbance in colorimetric assay using CCK-8 (Fig. 1E), these results suggested that miR-3074-3p promoted myogenesis in a cell cycle-independent manner.

**Fig. 2.** miR-3074-3p inhibited Cav1 expression by directly binding to the Cav1 3’ UTR. (A) The miR-3074-3p binding site (red) in the mouse Cav1 3’ UTR (position 1793-1800) is conserved in the human Cav1 3’ UTR (position 1813-1820). (B) Effects of miR-3074-3p on the activity of luciferase reporters bearing wild-type (WT) or a deletion mutant (Mut) of its binding site for Cav1 3’ UTR. **P < 0.01. (C) Immunoblots of Cav1 and Cav3 in (left) primary myoblasts and (right) C2C12 cells transfected with M-miR-3074-3p or M-Ctrl. (D) (left) Relative expression of miR-3074-3p and (right) protein content of Cav1 in C2C12 cells cultured in growth medium (GM) or differentiation medium (DM). ACTB was used as a loading control. *P < 0.05.
miR-3074-3p was significantly decreased after induction of differentiation in C2C12 cells. Consistent with the decreased expression of miR-3074-3p, the protein content of Cav1 was increased in differentiating C2C12 cells (Fig. 2D). Collectively, these findings suggest that miR-3074-3p regulates the expression of Cav1 protein by directly binding to its 3' UTR.

**Caveolin-1 negatively regulates myogenic differentiation in C2C12 cells**

To further evaluate whether Cav1 is involved in myogenesis, we inhibited Cav1 expression using small interfering RNA (siCav1) in C2C12 cells and then induced muscle differentiation. Consistent with the results obtained using M-miR-3074-3p, knockdown of Cav1 significantly promoted myogenesis, resulting in increased expression of myogenic marker genes (Fig. 3A) and proteins (Fig. 3B). In addition, inhibition of Cav1 expression significantly promoted myotube formation (Fig. 3C). In contrast, overexpression of Cav1 using adenovirus expressing CAV1 (Ad-CAV1) inhibited myogenesis, resulting in significantly downregulated myogenic markers (Fig. 3D). These results strongly suggest that Cav1 negatively regulates myogenesis.

**miR-3074-3p promotes myogenesis of HSMMs**

Since the miR-3074-3p seed sequence is conserved between the human and mouse Cav1 3' UTR (Fig. 2A), we hypothesized that miR-3074-3p might also be able to regulate human CAV1 expression levels. We thus analyzed CAV1 protein levels and differentiation in HSMMs transfected with miR-3074-3p mimic (M). Consistent with the results in mouse myoblasts, M-miR-3074-3p downregulated the CAV1 protein levels (Fig. 4A) and upregulated the expression levels of myogenic markers such as MYOG and MYH1 (Fig. 4B). Consistently, knockdown of CAV1 significantly upregulated the expression levels of MYOG and MYH1 (Fig. 4C). Taken together, these findings suggest that miR-3074-3p promotes myogenesis in HSMMs via regulating the expression of CAV1.

**DISCUSSION**

Myogenesis is tightly regulated by myogenic regulatory factors (MRFs), such as MyoD, Myogenin, MRF4 and Myf5 (25-27). In addition to MRFs, several miRNAs that are differentially expressed during myogenic differentiation have been reported to regulate myogenesis by binding the 3' UTR of target genes. These miRNAs have emerged as key players in skeletal muscle myogenesis by participating in multiple gene regulation processes (28). miR-146b, one of the miRNAs upregulated during satellite cell activation and myoblast differentiation, has been reported to promote myogenic differentiation by targeting Smad4, Notch1, and Hrnga2 (29), miR-26a is also upregulated during myogenesis and promotes myogenesis by targeting Ezh2, a known suppressor of skeletal muscle cell differentiation (30). In this paper, we report for the first time that miR-3074-3p, which is differentially expressed during myogenesis, is a positive myogenic regulator targeting Cav1. Although a few reports have described miRNA profiling of differentiating C2C12 cells and their function to date (31, 32), our study is the first to analyze miRNA profiles using myoblasts and muscle tissues freshly isolated...
from mouse hindlimb to exclude artifacts originating from cell lines. Our profiling results revealed that the expression patterns of miRNAs, such as miR-1, miR-133, miR-31, miR-206, and miR-486, were similar in myogenesis, as described previously (13, 31-33). Notably, we identified a novel miRNA, miR-3074-3p, in our analysis and demonstrated its function in muscle differentiation. We believe that our profiling data will be valuable for studying the roles of miRNAs in muscle differentiation and complement previous profiling data using cell lines.

Caveolins, principal components of caveolae, are required for small invagination of the plasma membrane in most cell types (34). Caveolae acts as a signaling platform that recruits numerous signaling molecules, such as insulin receptor, mitogen-activated protein kinase and epidermal growth factor receptor. Cav1, one of the caveolin genes, is most prominently expressed in endothelial cells, adipocytes and smooth muscle cells. Cav1 forms a homo-oligomer or a hetero-oligomer with Cav2 and functions as a scaffolding protein that binds to signaling molecules through its caveolin scaffolding domain, thereby activating or inhibiting signaling pathways (35). However, the role of Cav1 in skeletal muscle is largely unknown. A previous report showed that Cav1 was downregulated in differentiated myotubes treated with dexamethasone, resulting in the suppression of insulin signaling and the subsequent upregulation of MAFbx/Atrogin1 and MuRF1 (36). During muscle regeneration, HGF is released from injured fibers and downregulates Cav1 expression in satellite cells. D. Volonte et al. suggested that Cav1 might be not only a structural protein component of caveolae but also a key player in muscle regeneration. These previous reports suggested possibility that Cav1 may play different roles in myoblasts and myotubes. Although the downregulation of Cav1 has been shown to activate ERK and promote muscle regeneration by stimulating satellite cell proliferation (24), in the present study, miR-3074-3p had no significant effect on cellular proliferation. We therefore concluded that miR-3074-3p promotes myogenesis in a cell cycle-independent manner. Future investigation into the precise mechanism underlying Cav1-dependent regulation in myogenesis may provide valuable insight for the development of therapeutics to combat muscle diseases.

In the present study, we found that conserved miR-3074-3p regulated Cav1 expression in C2C12 cells and HSMMs, thereby enhancing myogenesis. Collectively, our results suggest that miR-3074-3p may act as a positive regulator of myogenesis via fine-tuning Cav1 expression and may have the potential to promote muscle regeneration.

MATERIALS AND METHODS

miRNA sequencing and analysis
Small RNA-enriched total RNA from mouse myoblast (n = 4) and gastrocnemius muscle (n = 6) samples was extracted using the mirVana miRNA isolation kit (Ambion, Austin, TX) according to the manufacturer’s protocol, and miRNA libraries were prepared following the Illumina library preparation protocol (Illumina Inc., San Diego, CA, USA) as previously described (20). Mirbase was used to filter known miRNAs, and Rattus norvegicus was used as a related species. Experiments with mice were performed according to established protocols approved by the Animal Care and Use Committee of KORIB.

Cell culture
Primary myoblasts were isolated from hind limb muscles as described previously (37). Differentiation of primary myoblasts was induced by culturing cells in differentiation medium comprising DMEM (Gibco) supplemented with antibiotics and 5% horse serum (Gibco). C2C12 cells (ATCC) were cultured in DMEM (Gibco) with amphotericin B-penicillin-streptomycin and 10% FBS (Gibco). Human Skeletal Muscle Myoblasts (Lonza Walkersville, Inc.) were cultured in SKBM-2 (Lonza) supplemented with growth factors (Lonza). At 48-48 hr after transfection, differentiation was initiated by changing the medium to differentiation medium containing DMEM/F12 (Gibco), antibiotics, and 2% horse serum (Gibco). To overexpress Caveolin-1 in C2C12 cells, cells were infected with adenovirus expressing Caveolin-1 (Ad-Cav1) or control (Ad-Ctrl) by 30 MOI. After 24 hr of infection, myoblast differentiation was induced by changing the growth medium to differentiation medium.

Cell proliferation assay
C2C12 cells in 24-well plates at 1 × 10^5/well were transfected with 30 nM M-miR-3074-3p or M-Ctrl. After 24 or 48 hr, the cultured medium was transferred into 96-well plates, then CCK-8 (Dojindo) was added into each well the cells. After incubation for 1 hr, the absorbance was measured at 450 nm using SpectraMax M2e microplate reader (Molecular Devices).

Transfection and luciferase assay
siRNAs or miRNA mimics were transfected into primary myoblasts, C2C12 myoblasts, or HSMMs using RNAiMAX (Invitrogen) according to the manufacturer’s protocol. miRNA mimics were purchased from mirVana (MC18636, Invitrogen) or AccuTarget (M0014181, Bioneer). siRNAs were purchased from AccuOligo (1334902, Bioneer). Mimics of miRNA and siRNA (30-100 nM each) were transfected into primary myoblasts, C2C12 or HSMMs using RNAiMAX (Invitrogen) according to the manufacturer’s recommended protocols.

For the luciferase assays, the wild-type 3’ UTR fragment of Cav1 mRNA and the deletion mutant 3’ UTR fragment of Cav1 mRNA were cloned into pmirGLO (Promega). Each of the vectors was cotransfected with 30 nM M-miR-3074-3p or M-Ctrl into 293T cells by using Lipofectamine 2000 (Invitrogen). After 48 hr of transfection, cell lysates were used for the luciferase assay with the Dual-Luciferase Reporter Assay System (Promega) and Victor X3 (Perkin Elmer).
to standard protocols. Quantitative RT-PCR was performed using StepOnePlus™ (Applied Biosystems). Data were normalized to 36B4 or GAPDH mRNA levels in each reaction. The sequences of the PCR primers are as follows: Mouse 36B4 Forward: AGATCGGGGATGCTGTTGG, Mouse 36B4 Reverse: AAA GCCTGGAGAAGAGGCT; Mouse Cav1 Forward: ACGAT GTCTGGGGGCAATAAC, Mouse Cav1 Reverse: TCATATCTC TTTCTGCGTGC; MyoD Forward: ACTACATGGGCGACTCA GATGC, MyoD Reverse: CGCGTGATCACGTGC; Human MYOG Forward: CTACAGGCTTGGTCTACGCT, Myogenin Forward: CGGGGTGCTATGAGGTC; Human MYH1 Forward: ACTACAGTGGCGACTCA GTG, Human MYH1 Reverse: TTGATTTTGGAG GGAT; Human MYHC Forward: AAAAAAGGCCATCACTGACGC, Reverse: ACGATGGACGTAAGGGAGTG; Human ACTB Forward: ACTACAGTGGCGACTCA GTG, Human ACTB Reverse: TTGATTTTGGAG GGAT; Human GAPDH Forward: GAGTCAACGTAAGGGAGTG, Reverse: TTGATTTTGGAG GGAT; Human U6 snRNA Forward: AGATTCGGGATATGCTGTTGG, Mouse U6 snRNA Forward: AGATTCGGGATATGCTGTTGG, Mouse U6 snRNA Reverse: AAAAGGCCATCACTGACGC, Reverse: ACGATGGACGTAAGGGAGTG; Mouse GAPDH Forward: GAGTCAACGTAAGGGAGTG, Reverse: TTGATTTTGGAG GGAT; Mouse MYHC Forward: AAAAAAGGCCATCACTGACGC, Reverse: ACGATGGACGTAAGGGAGTG; MyoD Forward: ACTACATGGGCGACTCA GATGC, MyoD Reverse: CGCGTGATCACGTGC; Human GAPDH Forward: GAGTCAACGTAAGGGAGTG, Reverse: TTGATTTTGGAG GGAT; Human U6 snRNA Forward: AGATTCGGGATATGCTGTTGG, Mouse U6 snRNA Forward: AGATTCGGGATATGCTGTTGG, Mouse U6 snRNA Reverse: AAAAGGCCATCACTGACGC, Reverse: ACGATGGACGTAAGGGAGTG; Mouse GAPDH Forward: GAGTCAACGTAAGGGAGTG, Reverse: TTGATTTTGGAG GGAT; Mouse MYHC Forward: AAAAAAGGCCATCACTGACGC, Reverse: ACGATGGACGTAAGGGAGTG; MyoD Forward: ACTACATGGGCGACTCA GATGC, MyoD Reverse: CGCGTGATCACGTGC;

**REFERENCES**

1. Mauro A (1961) Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9, 493-495
2. Relaix F and Zammit PS (2012) Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 139, 2845-2856
3. Bernet JD, Doles JD, Hall JK, Kelly Tanaka K, Carter TA and Olwin BB (2014) p38 MAPK signaling underlies a cell-autonomous loss of stem cell self-renewal in skeletal muscle of aged mice. Nat Med 20, 265-271
4. He WA, Berardi E, Cardillo VM et al (2013) NF-kappaB-mediated Pax3 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 123, 4821-4835
5. Blau HM, Webster C and Pavlath GK (1983) Defective myoblasts identified in Duchenne muscular dystrophy. Nature 268, 350-355
6. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297
7. Ambros V (2004) The functions of animal microRNAs. Nature 431, 350-355
8. O'Rourke JR, Georges SA, Seay HR et al (2007) Essential role for Dicer during skeletal muscle development. Dev Biol 311, 359-368
9. Eisenberg I, Eran A, Nishino I et al (2007) Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A 104, 17016-17021
10. Thum T, Galuppo P, Wolf C et al (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267
11. Dey BK, Gagan J, Yan Z and Dutta A (2012) miR-26a is required for skeletal muscle differentiation and regeneration in mice. Genes Dev 26, 2180-2191
12. Liu N, Williams AH, Maxeiner JM et al (2012) microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J Clin Invest 122, 2054-2065
13. Cheung TH, Quach NL, Charville GW et al (2012)
Maintenance of muscle stem-cell quiescence by microRNA-489. Nature 482, 524-528
14. Callis TE, Chen JF and Wang DZ (2007) MicroRNAs in skeletal and cardiac muscle development. DNA Cell Biol 26, 219-225
15. McCarthy JJ and Esser KA (2007) MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol (1985) 102, 306-313
16. McCarthy JJ, Esser KA, Peterson CA and Dupont-Versteegden EE (2009) Evidence of MyomiR network regulation of beta-myosin heavy chain gene expression during skeletal muscle atrophy. Physiol Genomics 39, 219-226
17. Townley-Tilson WH, Callis TE and Wang D (2010) MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 42, 1252-1255
18. McCarthy JJ (2011) The MyomiR network in skeletal muscle plasticity. Exerc Sport Sci Rev 39, 150-154
19. Bagheri A, Khorram Khorshid HR, Mowla SJ et al (2017) Altered miR-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer. Avicenna J Med Biotechnol 9, 189-195
20. Kim JY, Park YK, Lee KP et al (2014) Genome-wide profiling of the microRNA-mRNA regulatory network in skeletal muscle with aging. Aging (Albany NY) 6, 524-544
21. Lee KP, Shin YJ, Panda AC et al (2015) miR-431 promotes differentiation and regeneration of old skeletal muscle by targeting Smaod4. Genes Dev 29, 1605-1617
22. Han J, Lee Y, Yeom KH, Kim YK, Jin H and Kim VN (2004) The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 18, 3016-3027
23. Volonte D, Liu Y and Gagliani F (2005) The modulation of caveolin-1 expression controls satellite cell activation during muscle repair. FASEB J 19, 237-239
24. Sabourin LA and Rudniki MA (2000) The molecular regulation of myogenesis. Clin Genet 57, 16-25
25. Sartorelli V and Caretti G (2005) Mechanisms underlying the transcriptional regulation of skeletal myogenesis. Curr Opin Genet Dev 15, 528-535
26. Wang YX and Rudniki MA (2011) Satellite cells, the engines of muscle repair. Nat Rev Mol Cell Biol 13, 127-133
27. Ge Y and Chen J (2011) MicroRNAs in skeletal myogenesis. Cell Cycle 10, 441-448
28. Khanna N, Ge Y and Chen J (2014) MicroRNA-146b promotes myogenic differentiation and modulates multiple gene targets in muscle cells. PloS One 9, e100657
29. Wond CF and Tellam RL (2008) MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 283, 9836-9843
30. Chen JF, Mandel EM, Thomson JM et al (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38, 228-233
31. Sun Y, Ge Y, Drnevich J, Zhao Y, Band M and Chen J (2010) Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J Cell Biol 189, 1157-1169
32. Dey BK, Gagan J and Dutta A (2011) miR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol 31, 203-214
33. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR and Anderson RG (1992) Caveolin, a protein component of caveolae membrane coats. Cell 68, 673-682
34. Parton RG and Simons K (2007) The multiple faces of caveolae. Nat Rev Mol Cell Biol 8, 185-194
35. Han DS, Yang WS and Kao TW (2017) Dexamethasone treatment at the myoblast stage enhanced C2C12 myocyte differentiation. Int J Med Sci 14, 434-443
36. Rando TA and Blau HM (1994) Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 125, 1275-1287
37. Park SY, Yun Y, Lim JS et al (2016) Stabilin-2 modulates the efficiency of myoblast fusion during myogenic differentiation and muscle regeneration. Nat Commun 7, 10871